AMSER Rad-Path Case of the Month:

67-year-old female with cough, congestion, confusion, and difficulty speaking

Zachary Brandt, MS-3 Creighton University School Of Medicine

Nastaran Shahsavari, MD Creighton University School Of Medicine - Department of Radiology

M. Adelita Vizcaino, MD Mayo Clinic – Department of Laboratory Medicine and Pathology

Amir Nazem, MD PhD Mayo Clinic – Department of Laboratory Medicine and Pathology

Erik Pedersen, MD Creighton University School Of Medicine - Department of Radiology







School of Medicine

Patient Presentation

HPI:

- 67-year-old female presented to her primary care physician for evaluation of cough, congestion, and confusion ongoing for two weeks and worsening over the prior 24 hours
- Patient's family endorses lagging speech and inability to answer questions
- Negative for nausea or vomiting, headache, weakness, vision changes, or sensory deficits

Physical Exam:

- Notable delay in response to complex questions, suspicious for expressive aphasia
- Patient orientated to person, time, and place. Able to follow commands appropriately. Motor and sensory function intact. Cranial nerves intact.



Patient Presentation

PMHx & PSHx:

- The patient has a past medical history of CKD stage III, hyperlipidemia, hypertensive renal disease, hypothyroidism s/p graves s/p radioiodine ablation, immune thrombocytopenia, and psoriasis
- The patient's past surgical history is unremarkable

Abnormal Labs		
Potassium	3.1 (3.7-5.1 mmol/L)	
Creatinine	1.66 (0.50-1.10 mg/dl)	
BUN	31 (6 - 24 mg/dl)	
eGFR	34 (≥90 mL/min/1.73m²)	



What Imaging Should We Order?



Select the applicable ACR Appropriateness Criteria

Variant 1:Acute mental status change. Increased risk for intracranial bleeding (ie, anticoagulant use, coagulopathy), hypertensive emergency, or clinical suspicion for intracranial infection, mass, or elevated intracranial pressure. Initial imaging.

Procedure	Appropriateness Category	Relative Radiation Level
CT head without IV contrast	Usually Appropriate	\$ \$ \$
MRI head without IV contrast	Usually Appropriate	0
MRI head without and with IV contrast	May Be Appropriate	0
CT head without and with IV contrast	May Be Appropriate	\$ \$ \$
CT head with IV contrast	Usually Not Appropriate	* * *



Head CT Without Contrast (Unlabeled)





Head CT Without Contrast (Labeled)



Axial CT image of the head showing a 3 cm hypodense region within the left frontal subcortical white matter




Select the applicable ACR Appropriateness Criteria

Variant 2:Acute or progressively worsening mental status change in patient with a known intracranial
process (mass, recent hemorrhage, recent infarct, central nervous system infection, etc).
Initial imaging.


Procedure	Appropriateness Category	Relative Radiation Level
CT head without IV contrast	Usually Appropriate	* * *
MRI head without and with IV contrast	Usually Appropriate	0
MRI head without IV contrast	Usually Appropriate	0
CT head without and with IV contrast	May Be Appropriate	\$ \$ \$
CT head with IV contrast	May Be Appropriate	* * *



MRI Brain With and Without Contrast (Unlabeled)




MRI Brain With and Without Contrast (Labeled)



(A) Axial T2-weighted MR image of the brain showing a moderate sized geographic area of intra-axial signal hyperintensity at the left frontal subcortical white matter. (B) Axial diffusion-weighted MR image and (C) Axial ADC map of the brain showing elements of '<u>leading edge restricted diffusion'</u>




MRI Brain With and Without Contrast (Unlabeled)






MRI Brain With and Without Contrast (Labeled)



A-C. Axial FLAIR MR images showing <u>multifocal signal</u> <u>abnormalities</u> throughout the cerebral white matter most notably in the left frontal and left occipital regions

RMSER

MRI Brain With and Without Contrast (Unlabeled)




January

February



MRI Brain With and Without Contrast (Labeled)



Axial T2 weighted MR images one month apart showing progressive disease



January

Differential

Progressive Multifocal Leukoencephalopathy

Acute Disseminated Encephalomyelitis



Case Progression


- LP showed clear fluids with no indicators of meningitis or encephalitis, no cells, mild elevated glucose and no proteins.
- JC virus DNA detection test was <u>negative in the CSF</u>

Abnormal Labs During Further Workup		
CD4 T Cell Count	76 (365-1437 cells/mcL)	
IgM	27 (37-286 mg/dL)	
lgG	743 (767-1590 mg/dL)	

• Following a left frontal craniotomy with stereotactic biopsy, <u>JC in situ hybridization studies</u> resulted positive within oligodendrocytes


RMSER

H&E section on low magnification demonstrates a relatively demarcated macrophage-rich inflammatory lesion involving predominantly subcortical white matter.




Left Frontal Craniotomy with Stereotactic Biopsy

The subcortical white matter shows extensive chronic inflammation with prominent foamy histiocytes (yellow arrows) and small perivascular lymphocytes (blue arrows). Numerous reactive astrocytes with abundant eosinophilic cytoplasm are present in the background (arrowhead). Scattered oligodendrocytes show viral cytopathic changes with enlarged nuclei and margination of the chromatin (inset). Neurofilament immunostain highlights areas with axonal disruption and spheroid formation (red arrows).






Marked chronic inflammatory infiltrate composed predominantly of CD68-positive histiocytes and small, reactive Tlymphocytes highlighted by CD3 immunostain. Occasional CD20-positive small B-cells are also present.





The lesional cells are positive for JC virus *in-situ* hybridization and exhibit p53 nuclear overexpression, supporting the diagnosis of progressive multifocal leukoencephalopathy.



Final Dx:

Progressive Multifocal Leukoencephalopathy (PML)



PML

Basics:

- There is a reactivation of JC virus often triggered by immunosuppression, leading to oligodendrocyte infection, and aggressive replication within brain tissue causing demyelination and destruction of oligodendrocytes
- Prognosis is poor median survival in patients without HIV is 3 months

Risk Factors:

- Immunosuppression (Lymphoma, Leukemia, Organ Transplant, Autoimmune)
- HIV

Clinical Features:

• Focal neurologic deficits, isolated encephalopathy, behavioral changes, altered mental status, seizures, and vision changes



PML

Diagnostics:

- The diagnosis is usually made based on typical imaging findings
- Confirmatory testing with CSF analysis can be considered, but brain biopsy (although rare) is the gold standard for diagnosis

Radiographic Features

- MRI brain with and without gadolinium contrast is preferred. Images typically show multifocal, bilateral, asymmetric white matter lesions that are hypointense on T1, hyperintense on T2, and <u>without</u> mass effect (the lack of mass effect helps distinguish from primary CNS lymphoma and toxoplasmosis)
- Frontal, parietal, and occipital lobes are the most commonly involved
- Peripheral restricted diffusion at the leading edge
- CT brain with contrast shows focal hypodense white matter lesions



Treatment

- Treatment typically consists of supportive care and symptomatic treatment (eg. Seizures)
- In patients with HIV, antiretroviral treatment should be started immediately or optimized to improve immune status
- Monitor for Immune reconstitution inflammatory syndrome (IRIS) which may cause a paradoxical worsening of PML
- In our case, the patient has also benefitted greatly from occupational and speech therapy



Case Discussion

- This patient initially presented with altered mental status and confusion which later progressed to seizures. Her initial imaging showed classic signs of progressive multifocal leukoencephalopathy. Yet her <u>CSF analysis for JC virus DNA resulted negative twice</u>; however, it should be noted that this is not unheard of in PML, and false negatives can occur in up to 25% of routine PCR tests.
- In addition, there were no obvious causes of immunosuppression. <u>It is presumed that</u> <u>her low CD4 count is a result of an underlying idiopathic T-cell lymphopenia</u> which is an entity know to be associated with PML independent of the use of immunosuppressants or other autoimmune disease.
- Despite a very poor prognosis, this patient is doing well a year out from her initial presentation with improvement of symptoms.



Case Discussion: Pathology

Classic Triad

- Demyelination of axons
- Enlarged oligodendrocytes with intranuclear inclusions
- Bizarre astrocytes



References:

Dato, Clemente et al. "'Borderline' Idiopathic CD4+ T-Cell Lymphocytopenia Presenting with Atypical Progressive Multifocal Leukoencephalopathy." *Journal of neuroimmunology* 349 (2020): 577420–577420. Web.

Faulkner, Michele A. "Risk of Progressive Multifocal Leukoencephalopathy in Patients with Multiple Sclerosis." *Expert Opinion on Drug Safety* 14.11 (2015): 1–12. Web.

Fukumoto, Tatsuya et al. "'Burnt-out' Progressive Multifocal Leukoencephalopathy in Idiopathic CD4+ Lymphocytopenia." *Neuropathology* 41.6 (2021): 484–488. Web.

Plavina, Tatiana et al. "Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy." *Annals of neurology* 76.6 (2014): 802–812. Web.

Schweitzer, Finja et al. "Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy." *Neurology* 101.16 (2023): 700–713. Web.

White, Martyn K., and Kamel Khalili. "Pathogenesis of Progressive Multifocal Leukoencephalopathy—Revisited." *The Journal of infectious diseases* 203.5 (2011): 578–586. Web.

